Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRDX1 | Q06830 | 15/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | CCR6 | P51684 | 1/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.59 |
| ▸ | NR4A1 | P22736 | 3/20 | 0.59 |
| ▸ | TERT | O14746 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22010596 | 0.91 | PRDX1 (0.67) | PRDX1NR4A1TERTPTPN1CASP1 | |
| SCHEMBL22010609 | 0.91 | PRDX1 (0.68) | PRDX1NR4A1 | |
| SCHEMBL18781888 | 0.88 | PRDX1 (0.77) | PRDX1HSP90AA1CCR6PAX8TLR9 | |
| SCHEMBL22011631 | 0.88 | PRDX1 (0.57) | PRDX1HSP90AA1CCR6PAX8TLR9 | |
| SCHEMBL22010874 | 0.87 | HSP90AA1 (0.77) | HSP90AA1CCR6PAX8TLR9NR4A1 | |
| SCHEMBL21529185 | 0.86 | NR4A1 (0.78) | HSP90AA1CCR6PAX8TLR9NR4A1 | |
| SCHEMBL23490905 | 0.85 | NR4A1 (0.70) | PRDX1HSP90AA1CCR6PAX8TLR9 | |
| SCHEMBL22011634 | 0.85 | NR4A1 (0.79) | PRDX1HSP90AA1CCR6PAX8TLR9 | |
| SCHEMBL22010584 | 0.85 | TERT (0.79) | HSP90AA1CCR6PAX8TLR9NR4A1 | |
| SCHEMBL22010612 | 0.85 | NR4A1 (0.67) | HSP90AA1CCR6PAX8TLR9NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753436-B2 | Analogs of celastrol | ERX PHARMACEUTICALS CORPORATION (US) | 2023-09-12 | — | — | US | disclosed |
| US-10662218-B2 | Analogs of celastrol | ERX PHARMACEUTICALS CORPORATION | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662218-B2 | Analogs of celastrol | GIPR, GPR119, EBP | PRDX1 4176/4885HSP90AA1 123/4885CCR6 3242/4885 |
| US-11753436-B2 | Analogs of celastrol | GIPR, GPR119, EBP | PRDX1 4176/4885HSP90AA1 123/4885CCR6 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.